Bio Horizons is marketing Sriate+ directly on its homepage, page-71

Still there:




And soon to be added to this:

https://www.henryschein.co.uk/gb-en/dental-gb/m/ace-surgical-supply

How funny are markets that this stock ran to $0.49 shortly after I found Striate front and centre of BH's website and yet now, after announcing nearly 6,000 units sold for the quarter, more than the company or many of us expected, the stock trades $0.38.

Investors en masse really are funny things in their actions. If you do a study of the 4C's as previously discussed (hint look at the variable manufacturing costs) you will see the increased sales have yet to be properly reflected in cash receipts and therefore the 4C cash inflows. The accrued revenues/earnings reported at the end of this month will be dramatically different to past and an inflexion point for OCC as many have realised on here, marking its passage towards a positive free cash flow business and a self sustaining business i.e. no more dreaded CR's, which every pre-commercial bio-tech globally is being punished on in the credit squeeze.

Investors really are snatching defeat from the jaws of victory some 9 years after this company IPO'd.